BiOxyDyn is based at Manchester Science Park and was founded by Prof. Geoff Parker as a spin-out from the University of Manchester and UMIP’s Proof of Principle programme. The company has developed technology used in conjunction with MRI scans to produce better quality images, particularly of the lungs for diseases such as COPD and asthma. It is also active in developing new imaging tools for oncology and neuroscience. BiOxyDyn secured a £1.2m investment from The North West Fund for Biomedical (managed by SPARK Impact) and MTI Ventures’ UMIP Premier Fund (UPF). The company intends to use the funding to expand its imaging service business and to develop its technology into a diagnostic product. BiOxyDyn has developed an innovative approach to 3D lung imaging using enhanced magnetic resonance imaging (MRI) that exposes patients to zero radiation compared with CT scans. The company’s lung scans are positioned to aid diagnosis and monitoring of Chronic Obstructive Pulmonary Disease (COPD) and asthma. BiOxyDyn is based in the Core Technology Facility at the University of Manchester. The company has opened negotiations with a major pharmaceutical company, indicating potential commercial or collaborative opportunities. Financially, BiOxyDyn has received an undisclosed financing from MTI Partners’ UMIP Premier Fund. The deal was reported alongside a prior MTI investment in a different University of Manchester spin-out, Ai2.

Total raised

$2M

Funding rounds

2

Latest round

Equity

Latest activity

Oct 2012